Vivesto (VIVE) investor relations material

Executive summary

• Achieved key milestones in both Paccal Vet and Cantrixil development programs, with all prioritized projects progressing as planned into the second half of 2026.

• Completed recruitment for the Paccal Vet pilot study in dogs with hemangiosarcoma; topline results expected in Q3 2026.

• Positive results reported from Cantrixil PK/toxicology study in dogs, supporting further clinical development for AML in humans and a pilot study in canine cancer.

• Recruitment finalized for Paccal Vet dose-escalation study in cats; final results expected Q4 2026.

• Strengthened management with new CFO appointment and completed a 1:100 reverse stock split and share capital reduction.

Financial highlights

• Net sales were SEK 0 thousand (0) for both Q2 and H1 2026.

• Operating loss for Q2 was SEK -8,626 thousand (Q2 2025: -9,739); H1 operating loss was SEK -15,415 thousand (H1 2025: -18,327).

• Net loss after tax for Q2 was SEK -8,383 thousand (Q2 2025: -9,526); H1 net loss was SEK -15,276 thousand (H1 2025: -17,814).

• Earnings per share for Q2: SEK -0.76 (-1.77); H1: SEK -1.51 (-3.31).

• Cash and short-term investments at period end: SEK 23,514 thousand (4,221).

• Equity ratio at period end: 94% (92%).

Outlook and guidance

• All prioritized development programs are on track, with several important results expected in the coming months.

• Topline results from Paccal Vet dog study expected in Q3 2026; final results from cat study and further Cantrixil data expected in Q4 2026.

• Business development and partnership discussions are intensifying, aiming for value-creating collaborations.

• Current funding is expected to support operations until Q2 2027.